3B BlackBio Dx Ltd

Key financial & operational highlights

• Consolidated Q1 FY27 Revenue from Operations: ₹3,349.08 Lakhs.
• PBT: ₹1,321.95 Lakhs; PAT: ₹897.84 Lakhs.
• EPS: ₹10.48 consolidated in Q1 FY27.
• Consolidated revenue excluding Coris: ₹2,486.24 Lakhs.
• PBT (excl. Coris): ₹1,791.76 Lakhs; PAT: ₹1,367.66 Lakhs.
• EPS (excl. Coris): ₹15.96.
• Export agrochemicals: ₹58.99 Lakhs in Q1 2026-27; ₹53.58 in Q1 2025-26.
• MDx portfolio: 120+ assays; presence in 70+ countries.
• India MDx reach: 1,000 labs across 100+ cities.
• Capacity utilization: ~65% current; ~50% lean season.
• Coris Q1 2026-27 revenue: €0.796m; EBITDA loss: €0.325m.
• HAT order confirmation: €1.41m for Q3 2026.
• HAT Belgium contract: €6.0m to be supplied over four years.
• IVDR: legacy sales until 31 Dec 2028; BSI Notified Body appointed.
• Long-term reagent contracts: >15; revenue share 20-25%.
• Global MDx reach: 70+ countries; India labs across 100+ cities.
• Capacity expansion and M&A: pursuing global opportunities; Coris acquisition completed Aug 2025.

Financial results

• Standalone revenue from operations: Rs 2,294.52 Lakhs.
• Standalone total income: Rs 2,824.79 Lakhs.
• Standalone PBT: Rs 1,835.32 Lakhs.
• Standalone PAT: Rs 1,441.21 Lakhs.
• Standalone Basic EPS: Rs 16.41; Diluted EPS: Rs 16.47.
• Consolidated revenue from operations: Rs 3,349.08 Lakhs.
• Consolidated total income: Rs 3,963.38 Lakhs.
• Consolidated PBT: Rs 1,321.95 Lakhs.
• Consolidated PAT: Rs 897.84 Lakhs.
• Consolidated Basic EPS: Rs 10.48; Diluted EPS: Rs 10.48.
• Board approves M/s Sanjay Kasliwal & Associates as Cost Auditor for FY2026-27.
• Remuneration for Cost Auditor to be placed before shareholders for ratification.
• Limited Review of standalone and consolidated results completed.
• Two reportable segments: Agrochemicals and Molecular Diagnostic Kits.
• Agrochemical business is seasonal and weather may impact results.

Meeting Details

• Date: 13 August 2026; Time: 3:00 PM; Location: Registered office, Govindpura, Bhopal.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for Q1 ended 30 June 2026.

Other Notes

• Trading window closed from 1 July 2026 to 48 hours after results announced on 13 August 2026.

KYC compliance for physical holders

• This notice requires physical shareholders to furnish mandatory KYC details to the Registrar and Transfer Agent.
• Compliance is under SEBI LODR and applicable circulars.
• Submit documents immediately to Adroit Corporate Services.
• Required fields include PAN, address, email, mobile, Demat, bank details, signature, and nomination.
• Shareholders may opt out nomination using ISR-3; SH-13 becomes unnecessary.
• Dividend payments may be electronic if nomination is not submitted.
• Submit documents to Adroit Corporate Services, Unit: 3B BlackBio Dx Ltd, Mumbai.
• KYC forms are downloadable from the company investor page and the RTA site.
• Assistance is available via Adroit Corporate Services contact details.
• Date of intimation is July 9, 2026.

Reg 74(5) dematerialisation update

• Securities for dematerialisation received during quarter ended 30 June 2026 were processed and confirmed to depositories.
• Securities dematerialised have been listed on stock exchanges where the prior securities are listed.
• Physical certificates for dematerialisation were mutilated and cancelled, with depository's name substituted as owner within 15 days.

Business

• 3B BlackBio Dx develops molecular diagnostic kits and agrochemical products.
• Operations span India, exports, and subsidiaries in the UK and Belgium.

Financials

• FY26 revenue rose to ₹13,111.81 lakh from ₹8,428.25 lakh.
• FY26 EBITDA was ₹8,219.13 lakh; PAT was ₹6,003.07 lakh.
• Consolidated FY26 revenue was ₹14,191.81 lakh; PAT was ₹5,992.98 lakh.
• EPS increased to ₹69.94 from ₹55.66 in FY25.

Operations

• MDx has 120+ assays, serving 1,000+ labs and hospitals across 70+ countries.
• Exports grew 25% to ₹2,140.94 lakh, despite Middle East cancellations.
• Agrochemical exports fell 22% to ₹277.74 lakh due to Bangladesh tensions.
• Coris acquisition added sales and one-time HAT order-related profit.

Outlook

• Management targets 15%-20% overall growth in FY27, with slight positive EBITDA.
• TRUPCR Europe is a growth driver, with 36% sales growth in FY26.
• IVDR transition is underway; BSI QMS audits were passed in November 2025.
• New launches include AMR, dPCR, and NGS assays, plus a sample-to-answer system.

Liquidity

• Agro business operates with minimal debt.
• The company is pursuing M&A opportunities in the EU and USA.
• Reagent-rental contracts are expected to contribute 20%-25% of revenue.

Risks

• Competition is pressuring margins, especially in exports and infectious disease products.
• Geopolitical tensions disrupted Bangladesh and Middle East demand.
• Management expects new registrations to take 10-15 months before commercial orders.

Governance

• Nikhil Kuber Dubey signed the filing as Whole Time Director.
• The company changed its name to 3B BlackBio Dx Limited from Kilpest India Limited.

Q&A highlights

• 🗒️ No investor Q&A section was included in this chunk.